Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise specializing in the development and global commercialization of pharmaceutical products. Operating across Japan, Switzerland, the United States, Bermuda, and the United Kingdom, the company provides a range of established treatments. Its current commercialized offerings include Ultibro/Breezhaler and Seebri/Breezhaler, both prescribed for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler, which are utilized in asthma management. Additionally, the portfolio features ORAVI, an innovative formulation for treating oropharyngeal candidiasis, and PIVLAZ, indicated for cerebral vasospasm. Looking to the future, Nxera Pharma maintains a robust research and development pipeline. This includes investigational compounds such as HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia disorders, Daridorexant for insomnia, and HTL0016878 for schizophrenia and other neuropsychiatric conditions. Other prospective therapies include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, PF-06954522 for metabolic diseases, NBI-1117569 for neurology diseases, and NBI-1117570 for central nervous system (CNS) disorders. The company is also advancing a GPR35 agonist for inflammatory bowel disease/GI disorders, currently in its preclinical phase, alongside various other early-stage discovery and preclinical research programs. To further its initiatives, Nxera Pharma has forged strategic alliances with prominent industry partners, including AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. The company was founded in 1990 and its corporate headquarters are located in Tokyo, Japan.
—
Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise specializing in the development and global commercialization of pharmaceutical products. Operating across Japan, Switzerland, the United States, Bermuda, and the United Kingdom, the company provides a range of established treatments. Its current commercialized offerings include Ultibro/Breezhaler and Seebri/Breezhaler, both prescribed for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler, which are utilized in asthma management. Additionally, the portfolio features ORAVI, an innovative formulation for treating oropharyngeal candidiasis, and PIVLAZ, indicated for cerebral vasospasm. Looking to the future, Nxera Pharma maintains a robust research and development pipeline. This includes investigational compounds such as HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia disorders, Daridorexant for insomnia, and HTL0016878 for schizophrenia and other neuropsychiatric conditions. Other prospective therapies include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, PF-06954522 for metabolic diseases, NBI-1117569 for neurology diseases, and NBI-1117570 for central nervous system (CNS) disorders. The company is also advancing a GPR35 agonist for inflammatory bowel disease/GI disorders, currently in its preclinical phase, alongside various other early-stage discovery and preclinical research programs. To further its initiatives, Nxera Pharma has forged strategic alliances with prominent industry partners, including AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. The company was founded in 1990 and its corporate headquarters are located in Tokyo, Japan.
—
Daily adjusted close
Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise specializing in the development and global commercialization of pharmaceutical products. Operating across Japan, Switzerland, the United States, Bermuda, and the United Kingdom, the company provides a range of established treatments. Its current commercialized offerings include Ultibro/Breezhaler and Seebri/Breezhaler, both prescribed for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler, which are utilized in asthma management. Additionally, the portfolio features ORAVI, an innovative formulation for treating oropharyngeal candidiasis, and PIVLAZ, indicated for cerebral vasospasm. Looking to the future, Nxera Pharma maintains a robust research and development pipeline. This includes investigational compounds such as HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia disorders, Daridorexant for insomnia, and HTL0016878 for schizophrenia and other neuropsychiatric conditions. Other prospective therapies include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, PF-06954522 for metabolic diseases, NBI-1117569 for neurology diseases, and NBI-1117570 for central nervous system (CNS) disorders. The company is also advancing a GPR35 agonist for inflammatory bowel disease/GI disorders, currently in its preclinical phase, alongside various other early-stage discovery and preclinical research programs. To further its initiatives, Nxera Pharma has forged strategic alliances with prominent industry partners, including AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. The company was founded in 1990 and its corporate headquarters are located in Tokyo, Japan.